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ABSTRACT 
Background: Attention deficit/hyperactivity disorder (ADHD) is one of the most common 
behavioral disorders in  children.  Insufficient dietary intake of long-chain  polyunsaturated 
fatty  acids  (LC-PUFAs)  has  been  suggested  to  have  an  impact  on  the  development  of 
symptoms of ADHD in children. Individuals with ADHD have been demonstrated to have 
significantly reduced blood concentrations of PUFAs and, in particular, reduced levels of 
omega-3 (n-3) PUFAs. These findings suggest that PUFA supplementation may reduce the 
attention and behavior problems associated with ADHD. 
 
Objective: To provide an overview of the efficacy of dietary LC-PUFA supplementation in 
the treatment of ADHD. 
 
Methods:  Literature  published  up  until  December  2013  on  the  effects  of  n-3  PUFA 
supplementation on ADHD symptoms was obtained using a PubMed search and critically 
reviewed. 
 
Results:  Dietary  PUFA  supplementation  appears  to  have  beneficial  effects  on  ADHD 
symptoms  although  these  effects  are  small.  The  clinical  relevance  of  these  observations 
remains to be determined. 
 
Conclusion: There is only limited support for the efficacy of PUFA supplementation for the 
core symptoms of ADHD. Given the small effect sizes regarding PUFA supplementation, it 
may not be a sufficient therapy for a majority of patients with ADHD. 
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Background 
Attention  deficit/hyperactivity  disorder  (ADHD)  is  one  of  the  most  common  psychiatric 
disorders in childhood and adolescence and is characterized by age-inappropriate levels of 
inattention, impulsivity and hyperactivity, and is associated with long-term academic, social, 
and mental health problems. Approximately 3-5 % of school children and adolescents are 
affected by ADHD; the prevalence is higher in boys than girls [1-4]. Environmental, social, 
genetic and neurobiological factors appear to be relevant in the etiology of ADHD [1, 5, 6]. 
Neurobiological studies suggest that ADHD is a neurodevelopmental disorder involving 
dysfunctional neurotransmission of, among others, central dopaminergic systems [7-14]. For 
example, it has been proposed that a decrease in activity of frontal cortical dopaminergic 
neurotransmission  plays  a  role  in  regard  to  cognitive  deficits,  while  dopaminergic  over-
activity  in  sub-cortical  regions  may  lead  to  behavioral  hyperactivity  [2,  15].  Stimulant 
medications such as methylphenidate are the most frequently used treatments for ADHD, but 
these are not always effective and can be associated with side effects.  
The role of diet and dietary supplementation in the etiology and therapy of ADHD is 
controversial. ADHD has recently been linked with a Western-style diet which is high in fat, 
refined sugars and sodium and low in fiber, folate and omega-3 polyunsaturated fatty acids 
(n-3 PUFAs) [16]. Dietary treatments proposed in ADHD include sugar-restricted, additive- 
and salicylate-free, oligoantigenic, ketogenic, megavitamin, and PUFA supplement diets [17]. 
PUFA supplementation is the latest ADHD therapy to receive positive evaluations. 
 
Links between ADHD and PUFAs 
The  brain  relies  on  both  macro-  and  micro-nutrients  for  optimal  brain  development  and 
function [18]. PUFAs are known to play an important role in neuronal development and 
functioning of the central nervous system [19, 20]. The brain of mammals is particularly rich 
in  long-chain  (LC)  PUFAs  from  n-3  and  omega-6  (n-6)  families,  particularly 
docosahexaenoic  acid  (DHA,  C22:6ω-3)  and  arachidonic  acid  (AA,  C20:4ω-6)  [21,  22]. 
These PUFAs are synthesized by sequential desaturation and elongation of their respective 
precursors which cannot be synthesized by mammals and need therefore to be provided by 
the diet (essential fatty acids, EFAs). 
LC-PUFAs  such  as  eicosapentaenoic  acid  (EPA  C20:5ω-3),  DHA  and  AA  have  an 
influence on numerous neuronal processes, such as expression of proteins involved in signal 
transduction and neural plasticity and learning [19, 20, 23]. Increasing evidence points to the 
importance of nutrition, particularly n-3 PUFAs, for mental health. LC n-3 PUFAs may exert 
their  effects  on  cognitive  function  through  modulation  of  neuronal  membrane  which  can 
influence membrane receptors, neurotransmission and signal  transduction  [22]. Studies in 
humans indicate that a deficiency in n-3 fatty acids leads to an imbalance of the n-3/n-6 
PUFA ratio, affects neurocognitive abilities and is associated with developmental disorders 
such as ADHD [19, 20, 23, 24]. Effects of n-3 PUFAs have been explored on psychiatric 
problems  such  as  childhood  developmental  disorders,  depression,  schizophrenia  and 
dementia [25]. Mental disorders can lead to poor diet [26, 27] which could contribute to the 
PUFA  status  in  patients  with  psychiatric  problems.  In  this  context,  a  possibly  impaired 
metabolism of PUFAs has been discussed as a potential risk factor for the development of 
ADHD [19, 23]. 
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A  possible  link  between  ADHD  and  EFAs  was  first  proposed  on  the  basis  of  clinical 
observations. Hyperactive children had signs of fatty acid deficiency including polydipsia, 
polyuria as well as dry hair and skin [28]. These signs have been shown to be at least 30 % 
more frequent  in  children or  young adults  with ADHD than in  controls [29-32].  Further 
clinical and biochemical evidence suggests that deficiencies of PUFAs could be related to 
ADHD. For example, several studies demonstrated that blood plasma levels of fatty acids 
such  as  DHA,  EPA,  AA  and  dihomogammalinolenic  acid  (DGLA,  C20:3ω-6)  were 
significantly reduced in children with ADHD when compared with controls [29, 30, 33, 34]. 
The potential mechanisms leading to abnormal levels of EFAs in individuals with ADHD 
may include reduced PUFA intake, decreased  conversion of EFAs  to  LC-PUFAs and an 
increase in LC-PUFA metabolism [33]. However, none of these hypotheses are supported by 
convincing evidence. For example, no difference in the consumption of n-3 PUFAs could be 
demonstrated  in  patients  with  ADHD,  although  differences  in  n-3  PUFA  levels  in  both 
plasma  phospholipids  and  erythrocytes  were  found  [31].  The  above  mentioned  findings 
suggest  that  PUFA  supplementation  may  reduce  the  attention  and  behavior  problems 
associated  with  ADHD.  In  theory  n-3  PUFA  supplementation  may  offer  a  therapeutical 
approach  addressing  not  only  symptoms  but  also  an  underlying  etiological  factor.  As  a 
consequence, an increasing number of clinical studies have assessed the effects of PUFA 
supplementation on ADHD symptoms.  
 
Methods 
Literature published up until December 2013 on the effects of n-3 PUFA supplementation on 
ADHD symptoms was obtained using a PubMed search and critically reviewed. 
 
Dietary PUFA supplementation in ADHD 
Evidence for effects of dietary treatments of ADHD varies widely, from anecdotal evidence 
to  placebo-controlled  and  double-blind  trials.  Various  methodological  problems  make  it 
difficult  to  evaluate  clinical  trials  aimed  at  assessing  the  effects  of  dietary  PUFA 
supplementation in ADHD. There exists a great heterogeneity of several parameters including 
the  kind  of  fatty  acids  used  (EFA  precursors,  n-3  PUFAs,  n-6  PUFAs  or  combinations 
thereof),  the  form  in  which  the  supplement  is  administered,  the  dose  and  duration  of 
supplementation as well as the tests/assessments used to evaluate ADHD symptom prior to 
and following treatment. Not all studies investigated n-3 PUFA status before and after the 
intervention.  In addition, the diagnosis of ADHD was not always made according to the 
criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV, [35]) and 
various  comorbid  disorders  existed  in  numerous  subjects.  Since  some  studies  included 
subjects with ADHD under pharmacological therapy, it is difficult to draw conclusions as to 
the effects of an interaction between PUFA supplementation and stimulant medication. 
Using  meta-analysis  Bloch  and  Qawasmi  [36]  examined  the  efficacy  of  n-3  PUFA 
supplementation in children with ADHD. Ten trials involving 699 children were included. N-
3 PUFA supplementation demonstrated a small but significant effect in improving ADHD 
symptoms. N-3 PUFA supplementation, particularly with higher doses of EPA was modestly 
effective in the treatment of ADHD. The relative efficacy of n-3 PUFA supplementation was 
modest  compared  to  currently  available  pharmacotherapies  of  ADHD  such  as 
psychostimulants or atomoxetine [36].  
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Another meta-analysis by Gillies et al. [37] compared the efficacy of PUFAs to other 
forms  of  treatment  or  placebo  in  treating  the  symptoms  of  ADHD  in  children  and 
adolescents. Thirteen trials with 1,011 participants were included in the analysis. Overall, 
there was little evidence that PUFA supplementation provides any benefit for the symptoms 
of ADHD in children and adolescents. The majority of data showed no benefit of PUFA 
supplementation, although there were some limited data that did show an improvement with 
combined n-3 and n-6 supplementation [37].  
In  recently  published  meta-analyses,  Sonuga-Barke  et  al.  [38]  assessed  non-
pharmacological  interventions  for  ADHD.  The  authors  used  a  rigorous  methodology  by 
including only randomized controlled trials. In regard to PUFA supplementation, eleven trials 
met inclusion criteria. Five of these studies used n-3 supplements [24, 39-42], two involved 
n-6 supplements [43, 44] and four used supplements with both n-3 and n-6 PUFAs [45-48]. 
Supplementation  effects  were  significant  and  the  probably  blinded  assessment  effects 
remained significant when the analysis was limited to the nine trials with no/low medication 
[38]. It is, however, possible that the outcomes in the studies analyzed by Sonuga-Barke et al. 
[38] included individuals with attention problems who were incorrectly diagnosed as having 
ADHD or by the presence of co-occurring conditions. In addition, the authors noted that 
while their findings demonstrate the efficacy of PUFA supplementation, the effect size is less 
than that of medications, i.e. PUFA supplementation has a small but significant effect on 
symptoms. 
The standardized mean differences (effect sizes) for PUFA supplementation in the meta-
analysis by Sonuga-Barke et al. [38] were smaller than those reported by Bloch and Qawasmi 
[36] who included trials with non-ADHD populations. The studies by Sonuga-Barke et al. 
[38] and Gillies et al. [37] differed in regard to inclusion criteria, the number of studies 
included and the statistical model employed. The differences between the findings of meta-
analytical reviews highlight the sensitivity of results to small variations in protocol. 
Given the high prevalence of co-occurring conditions with ADHD, many individuals 
included  in  the  clinical  trials  of  PUFA  supplementation  may  have  had  comorbidities. 
Observations of other studies showed that treatment response varied based on the patients’ 
comorbid conditions [49]. It is possible that PUFA supplementation in some studies was 
insufficient to influence the PUFA content in the brain due to too low doses of PUFAs or too 
short durations of administration. In addition, it needs to be investigated whether there is a 
critical  age  at  which  PUFAs  are  supplemented.  In  a  rat  model  of  chronic  n-3  PUFA 
deficiency,  it  was  demonstrated  that  the  introduction  of  an  equilibrated  diet  through  the 
mother during the pre-/postnatal period was able to restore monoaminergic functions affected 
by the deficiency only if it occurred before the 21st day of life [50, 51]. These results suggest 
that  an  optimal  time  frame  for  PUFA  supplementation  might  also  exist  during  brain 
development in humans.  
 
Conclusions 
A link appears to exist between reduced PUFA levels and the occurrence of ADHD. PUFA 
supplementation appears to produce small but significant reductions in ADHD symptoms. 
The differences between the results of recent meta-analytical studies emphasize the need for 
caution when discussing the clinical relevance of small effects reported for the efficacy of 
PUFA supplementation [36-38]. 
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Various factors may have influenced the results of studies on PUFA supplementation in 
ADHD,  e.g.  heterogeneity  of  design  type,  type  of  PUFA  employed  (n-3  or  n-6  or 
combination),  dose  of  LC-PUFAs,  method  of  administration,  duration  of  treatment  or 
assessment of response. Future research needs to address various weaknesses of treatment 
studies of PUFA supplementation, which include relatively small sample sizes, variability of 
selection criteria, differences in the type and dosage of supplementation and short follow-up 
periods. Little is known about optimal ratio between supplemented PUFAs and the necessity 
of weight-adjusted doses. Moreover, ecologically valid outcome measures are needed [52]. 
Baseline  n-3  PUFA  status  may  influence  the  outcome  of  PUFA  supplementation  in 
ADHD. Whether or not individuals with low n-3 PUFA status are more responsive to dietary 
n-3  PUFA  supplementation  is  as  yet  not  resolved.  It  is  therefore  important  to  identify 
subgroups  of  individuals  who  may  most  likely  benefit  from  n-3  PUFA  supplementation, 
including those with lower baseline PUFA status. In addition, there may be a threshold n-3 
PUFA status above which dietary supplementation has little effect on outcome measures. In 
addition, the ratio between DHA, EPA and AA requires consideration in future studies. 
If an optimal time frame in early childhood exists for successful dietary supplementation 
of n-3 PUFAs as suggested by animal studies [50, 51], the administration of these compounds 
at the time of school-age diagnosis ADHD may come too late. Future studies may investigate 
if maternal prenatal LC-PUFA supplementation or dietary PUFA administration at young age 
are able to prevent the occurrence of ADHD or reduce the severity of symptoms.   
In  summary,  there  is  at  present  only  limited  support  for  the  efficacy  of  PUFA 
supplementation for the core symptoms of ADHD. Given the small effect size of PUFA 
supplementation, it may not be a sufficient therapy for a majority of patients with ADHD. 
 
Abbreviations:  arachidonic  acid  (AA),  attention  deficit/hyperactivity  disorder  (ADHD), 
dihomogammalinolenic acid (DGLA), docosahexaenoic acid (DHA), eicosapentaenoic acid 
(EPA),  essential  fatty  acids  (EFAs),  long-chain  polyunsaturated  fatty  acid  (LC-PUFA), 
omega-3 polyunsaturated fatty acid (n-3 PUFA), omega-6 polyunsaturated fatty acid (n-6 
PUFA)  
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